* Eplerenone. The U sustenance and...

* Eplerenone. The U sustenance and Drug Administration (FDA) has approved eplerenone (Inspra) for the treatment of high vital fluid pressure.

Eplerenone works on selectively blocking aldosterone receptors. Clinical studies intimate that aldosterone contributes to the unravelling and progression of hypertension. Eplerenone can be administered separately or in combination with other antihypertensive therapies.

Side tenors include dizziness, fatigue, influenza-like symptoms, diarrhea, and cough Eplerenone is contraindicated in characters with significant elevations of potassium, renal insufficiency, or diabetes associated with microalbuminuria, or who are taking potassium supplys or certain diuretics.

* Adefovir dipivoxil. The FDA has approved adefovir dipivoxil (Hepsera) for the treatment of chronic hepatitis B in adults with evidence of active viral replication and evidence of persistent elevations in serum aminotransferases (ALT or AST) evens or histologically active disease.

Adefovir is a nucleotide analog agent that make steady [i]or[/i] firms the replication of the hepatitis B virus in the body

used by all side effects include asthenia (weakness), headache, abdominal pain, nausea, flatulence, diarrhea, and dyspepsia.

As with other antiviral therapies for chronic hepatitis B physicians ne to monitor liver function for exacerbation of hepatitis following discontinuation of therapy.

COPYRIGHT 2003 American Academy of Family Physicians

COPYRIGHT 2003 Gale Group